153 related articles for article (PubMed ID: 14736706)
1. Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome.
McCartney CR; Bellows AB; Gingrich MB; Hu Y; Evans WS; Marshall JC; Veldhuis JD
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E902-8. PubMed ID: 14736706
[TBL] [Abstract][Full Text] [Related]
2. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
[TBL] [Abstract][Full Text] [Related]
3. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
[TBL] [Abstract][Full Text] [Related]
4. In-vivo ovarian androgen responses to recombinant FSH with and without recombinant LH in polycystic ovarian syndrome.
Cheung AP; Pride SM; Yuen BH; Sy L
Hum Reprod; 2002 Oct; 17(10):2540-7. PubMed ID: 12351525
[TBL] [Abstract][Full Text] [Related]
5. Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase.
Sagnella F; Apa R; Guido M; Villa P; Spadoni V; Miceli F; Lanzone A
Fertil Steril; 2009 May; 91(5):1857-63. PubMed ID: 18538325
[TBL] [Abstract][Full Text] [Related]
6. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
Arroyo A; Laughlin GA; Morales AJ; Yen SS
J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
[TBL] [Abstract][Full Text] [Related]
7. Pulsatile intravenous infusion of recombinant human luteinizing hormone under acute gonadotropin-releasing hormone receptor blockade reconstitutes testosterone secretion in young men.
Veldhuis JD; Iranmanesh A
J Clin Endocrinol Metab; 2004 Sep; 89(9):4474-9. PubMed ID: 15356050
[TBL] [Abstract][Full Text] [Related]
8. A preponderance of basic luteinizing hormone (LH) isoforms accompanies inappropriate hypersecretion of both basal and pulsatile LH in adolescents with polycystic ovarian syndrome.
Ropelato MG; Garcia-Rudaz MC; Castro-Fernandez C; Ulloa-Aguirre A; Escobar ME; Barontini M; Veldhuis JD
J Clin Endocrinol Metab; 1999 Dec; 84(12):4629-36. PubMed ID: 10599730
[TBL] [Abstract][Full Text] [Related]
9. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics.
Hayes FJ; Taylor AE; Martin KA; Hall JE
J Clin Endocrinol Metab; 1998 Jul; 83(7):2343-9. PubMed ID: 9661606
[TBL] [Abstract][Full Text] [Related]
10. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
Tosi F; Negri C; Perrone F; Dorizzi R; Castello R; Bonora E; Moghetti P
J Clin Endocrinol Metab; 2012 May; 97(5):1712-9. PubMed ID: 22419715
[TBL] [Abstract][Full Text] [Related]
11. Adrenal androgenic response to 2-hour ACTH stimulation test in women with PCOS.
Erel CT; Senturk LM; Oral E; Colgar U; Ertungealp E
Gynecol Endocrinol; 1998 Aug; 12(4):223-9. PubMed ID: 9798131
[TBL] [Abstract][Full Text] [Related]
12. Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome.
Piltonen T; Koivunen R; Perheentupa A; Morin-Papunen L; Ruokonen A; Tapanainen JS
J Clin Endocrinol Metab; 2004 Aug; 89(8):3769-75. PubMed ID: 15292303
[TBL] [Abstract][Full Text] [Related]
13. 17-Hydroxyprogesterone responses to human chorionic gonadotropin are not associated with serum anti-Mullerian hormone levels among adolescent girls with polycystic ovary syndrome.
Hou J; Cook-Andersen H; Su HI; Shayya R; Maas KH; Burt-Solorzano CM; Kumar A; Chang RJ
J Pediatr Endocrinol Metab; 2016 Jul; 29(7):835-40. PubMed ID: 27166718
[TBL] [Abstract][Full Text] [Related]
14. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
[TBL] [Abstract][Full Text] [Related]
15. Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma.
Fulghesu AM; Angioni S; Belosi C; Apa R; Selvaggi L; Ciampelli M; Iuculano A; Melis GB; Lanzone A
Clin Endocrinol (Oxf); 2006 Sep; 65(3):396-401. PubMed ID: 16918963
[TBL] [Abstract][Full Text] [Related]
16. Augmented frequency and mass of LH discharged per burst are accompanied by marked disorderliness of LH secretion in adolescents with polycystic ovary syndrome.
García-Rudaz MC; Ropelato MG; Escobar ME; Veldhuis JD; Barontini M
Eur J Endocrinol; 1998 Dec; 139(6):621-30. PubMed ID: 9916868
[TBL] [Abstract][Full Text] [Related]
17. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
Unlühizarci K; Keleştimur F; Bayram F; Sahin Y; Tutuş A
Clin Endocrinol (Oxf); 1999 Aug; 51(2):231-6. PubMed ID: 10468995
[TBL] [Abstract][Full Text] [Related]
18. Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome.
Maas KH; Chuan S; Harrison E; Cook-Andersen H; Duleba AJ; Chang RJ
Fertil Steril; 2016 Oct; 106(5):1252-1257. PubMed ID: 27473350
[TBL] [Abstract][Full Text] [Related]
19. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
20. LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.
Hohmann FP; Laven JS; Mulders AG; Oberyé JJ; Mannaerts BM; de Jong FH; Fauser BC
J Endocrinol Invest; 2005 Dec; 28(11):990-7. PubMed ID: 16483177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
